Perioperative treatment of oesophageal, oesophago-gastric adenocarcinoma: new standards of care and controversies
Journal Title: OncoReview - Year 2013, Vol 3, Issue 1
Abstract
Oesophageal, gastroesophageal and gastric cancers represent important diagnostic and therapeutic challenge. Even after radical surgical procedure (R0) 5-year survival remains unsatisfactory. It is assumed that perioperative chemo/radiotherapy eliminates local and distant micrometastases. This year (2012) a consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer was published as a result of the first EORTC St. Gallen International Expert Consensus. Despite a significant progress in the perioperative treatment of locally advanced cancers of upper digestive tract, results of several ongoing clinical trials that may further optimize systemic treatment of these malignancies are eagerly awaited.
Authors and Affiliations
Izabela Łasińska, Łukasz Kwinta, Maria Litwiniuk, Piotr Wysocki
Keywords
Related Articles
- EP ID EP53197
- DOI -
- Views 235
- Downloads 0
Application of molecular markers in the diagnostics of thyroid focal lesions – current state of knowledge
Thyroid nodular disease is a common disorder and affects about 20% of adult polish population. Due to the fact that methods currently applied in routine assessment of these changes often do not provide accurate diagnosis...
Selected aspects of gastrointestinal stromal tumors management with tyrosine kinase inhibitors
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract that most frequently affect the stomach and small intestine. In the past these tumors may have been misclassifi...
Merkel cell carcinoma
Merkel cell carcinoma (MCC) is a rare cutaneous malignancy, with aggressive behaviour. The discovery of MCC polyomavirus (MCPyV) provided a major insight into pathogenesis of MCC, as MCPyV is present in most MCC tumours....
Original vs generic drugs in treatment of chronic myeloid leukaemia
The beginning of the twenty-first century saw a breakthrough in haematology, oncology and general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic myeloid leukaemia. For the first time...
Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HE -1 and HER-2 tyrosine kinase receptors....